A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization

Timeline

Start

2024-11-13

Primary completion

2026-03-30

Completion

2026-03-30

Outcome

Outcome not reported

Stopped: “Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.”

Drugs

Indications